Roche Holding AG


  • Dec 22- The U.S. Food and Drug Administration approved Bristol-Myers Squibb Co's skin cancer drug, more than three months before the scheduled review date. The drug is the second PD-1 inhibitor to be approved by the FDA, the first being Merck& Co Inc's Keytruda in September. The FDA was scheduled to review the drug on March 30.

  • Europe closes mixed; Italian banks, health care weigh Friday, 19 Dec 2014 | 11:31 AM ET

    European shares closed mixed on Friday, with Italian banking stocks and the health care sector weighing on wider benchmarks.

  • Dec 12- Cempra Inc has no plans for now to sell itself, its CEO said, brushing off talk that the company is a potential target as big drugmakers set their sights on antibiotic developers. The deal stirred speculation that developers such as Cempra could also be takeover targets. I know a lot of other biotechs are, " Cempra Chief Executive Prabha Fernandes said in an...

  • Bad flu season: A prescription for growth? Wednesday, 10 Dec 2014 | 8:16 AM ET
    A mam receives an influenza shot from a Nurse Practitioner in the MinuteClinic at the CVS/pharmacy.

    The health-care sector tends to outperform the overall market during flu season. Who else stands to gain?

  • Paid doctor consultants swayed to use pricey drugs? Monday, 8 Dec 2014 | 11:11 AM ET
    Lucentis, produced by Genetech.

    Doctors who used Genentech's expensive eye drug Lucentis were also among the highest-paid consultants for the company, reports the New York Times.

  • Fighting kids' cancer, one voucher at a time Friday, 21 Nov 2014 | 10:03 AM ET
    Jacob with his parents Mike Froman and Nancy Goodman, and brother Ben (Spring 2008)

    There are few new cancer drugs to treat kids, and not much research is being done.

  • Nov 20- Global pharmaceutical spending will break the trillion dollar mark in 2014, driven by high prices in the United States for novel treatments such as Gilead Sciences Inc's Sovaldi for hepatitis C and new cancer drugs, according to a study released on Thursday. Total spending on drugs will hit $1.06 trillion, an increase of 7 percent over 2013 levels,...

  • German Merck, Pfizer in immunotherapy deal Monday, 17 Nov 2014 | 5:47 AM ET

    Germany's Merck KGaA said Monday it struck an alliance over cancer immunotherapy drugs with Pfizer, triggering an upfront payment of $850 million by the U.S. drugmaker.

  • Nov 16- Chemotherapy as a treatment for advanced melanoma could soon become obsolete, researchers said on Sunday, after patients taking an experimental immuno-oncology drug from Bristol-Myers Squibb Co had a much higher survival rate and had other favorable results. Georgina Long, an associate professor at the Melanoma Institute Australia who helped lead...

  • US pulls approval for these Nexium, Valcyte generics Thursday, 6 Nov 2014 | 9:47 AM ET

    The U.S. FDA has revoked a tentative approval for India's Ranbaxy to make a cheap copy of AstraZeneca's heartburn drug Nexium.

  • *Ranbaxy says FDA revoked approval for copies of Nexium, Valcyte. *FDA said approvals were given "in error"- Ranbaxy. The FDA has also stripped Ranbaxy of tentative approval and six-month exclusivity for a copy of Roche Holding AG's antiviral Valcyte, a fresh blow to the Indian company that has been hit by a raft of regulatory bans over poor production quality.

  • Alibaba’s market value surpasses Wal-Mart Tuesday, 28 Oct 2014 | 8:27 PM ET
    An employee walks past the Alibaba logo during a media tour organized by government officials at the company’s headquarters outside of Hangzhou, Zhejiang province, China.

    Alibaba muscled ahead of Wal-Mart by one important measure, when its market valuation surpassed the retailer by revenues. The Financial Times reports.

  • Drugmakers double down on Ebola vaccines, treatments Monday, 27 Oct 2014 | 7:31 AM ET
    People participate in a march, organized by New York’s West African community, to end Ebola, Oct. 24, 2014, in New York.

    Drugmakers are racing to develop vaccines and drugs to address Ebola, betting that governments and aid groups will foot the bill.

  • Oct 24- Bristol-Myers Squibb Co reported better-than-expected third-quarter results, as sizzling sales of its treatments for blood clots, cancer and arthritis helped offset sharply higher taxes. That compared with $692 million, or 42 cents per share, in the year-earlier period. Bristol-Myers, along with Merck& Co Inc, Roche Holding AG and AstraZeneca Plc are...

  • US STOCKS-Futures lower as weak IBM earnings weigh Monday, 20 Oct 2014 | 8:04 AM ET

    *IBM slumps after quarterly results. NEW YORK, Oct 20- U.S. stock index futures were lower on Monday, on the heels of a fourth week of losses for the benchmark S&P 500, as quarterly results from IBM disappointed. IBM shares slumped 7 percent to $169.24 as the most actively traded stock on the New York Stock Exchange in premarket after the company's third-quarter...

  • Oct 20- NewLink Genetics Corp said it entered into a licensing agreement with Roche Holding AG to develop NewLink's cancer immunotherapy, making the Ebola vaccine developer eligible to receive over $1 billion in milestone payments. NewLink's shares jumped nearly 26 percent before the bell on Monday. Immunotherapies are a class of drugs designed to help the...

  • WASHINGTON, Oct 16- Medicine costs would rise if draft proposals in a Pacific Rim trade pact come into force, health and consumer rights advocates said on Thursday after the release of a leaked negotiating text. The TPP's 12 members range from the United States and Japan to Malaysia and Vietnam, where equitable access to medicine is a priority, and Australia and...

  • Europe closes off lows, Greek bond yields near 9% Thursday, 16 Oct 2014 | 11:49 AM ET

    European shares closed lower on Thursday after trimming losses, tracking U.S. markets which partially recovered after visiting correction territory.

  • Roche sales beat forecasts, confirms outlook Thursday, 16 Oct 2014 | 3:34 AM ET

    Roche reported third quarter sales of 11.78 billion Swiss francs ($12.29 billion) on Thursday, above analysts' forecasts of 11.58 billion Swiss francs in a Reuters poll.

  • We're not looking at mega-mergers: Roche CEO  Thursday, 16 Oct 2014 | 2:45 AM ET

    Severin Schwan, CEO of Roche Group, says the company's "fundamental strategy" has not changed and is looking at "targeted" M&A deals.